Compare Inovio Pharmaceuticals Inc (INO) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Redwire Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $112.19M), while Redwire Corporation trades at $9.57 (market cap $2.44B). The key difference: Redwire Corporation is far larger — about 21.7× Inovio Pharmaceuticals Inc's market cap, and Redwire Corporation is more actively traded (11,053,212 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Redwire Corporation for 18 Days on average.
| INO | RDW | |
|---|---|---|
Market Cap | $112.19M | $2.44B |
Volume | 3,201,278 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $2.65 | $25.90 |
52-Week Low | $0.66 | $5.06 |
Typical Hold Time | 43 Days | 18 Days |
Enterprise Value | $83.51M | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Redwire Corporation (RDW) trades at $9.57, down 6.54% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, though revenue growth remains strong at 89.6% year-over-year. Recent developments include a $980 million Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data center technology.
Despite strong analyst support (80% buy ratings) and a $14.88 price target suggesting 55% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents high-risk speculation on space infrastructure growth, dependent on successful execution and SpaceX's Starship development timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
